Boston Common Asset Management’s Zimmer Biomet ZBH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-60,353
| Closed | -$6.83M | – | 312 |
|
|
2025
Q1 | $6.83M | Buy |
60,353
+10,601
| +21% | +$1.13M | 0.21% | 154 |
|
|
2024
Q4 | $5.26M | Buy |
49,752
+528
| +1% | +$56.7K | 0.15% | 168 |
|
|
2024
Q3 | $5.31M | Sell |
49,224
-3,667
| -7% | -$400K | 0.14% | 185 |
|
|
2024
Q2 | $5.74M | Sell |
52,891
-8,796
| -14% | -$1.04M | 0.15% | 175 |
|
|
2024
Q1 | $8.14M | Sell |
61,687
-36,249
| -37% | -$4.53M | 0.19% | 151 |
|
|
2023
Q4 | $11.9M | Sell |
97,936
-5,889
| -6% | -$657K | 0.27% | 126 |
|
|
2023
Q3 | $11.7M | Sell |
103,825
-2,925
| -3% | -$371K | 0.28% | 126 |
|
|
2023
Q2 | $15.5M | Sell |
106,750
-4,502
| -4% | -$612K | 0.33% | 111 |
|
|
2023
Q1 | $14.4M | Sell |
111,252
-23,608
| -18% | -$2.96M | 0.3% | 122 |
|
|
2022
Q4 | $17.2M | Buy |
134,860
+8,053
| +6% | +$935K | 0.82% | 47 |
|
|
2022
Q3 | $13.3M | Buy |
126,807
+6,922
| +6% | +$760K | 0.69% | 55 |
|
|
2022
Q2 | $12.6M | Buy |
119,885
+35,003
| +41% | +$4.15M | 0.63% | 58 |
|
|
2022
Q1 | $10.9M | Buy |
84,882
+28,247
| +50% | +$3.4M | 0.47% | 77 |
|
|
2021
Q4 | $6.99M | Buy |
56,635
+21,966
| +63% | +$2.87M | 0.28% | 97 |
|
|
2021
Q3 | $4.93M | Buy |
+34,669
| New | +$5.1M | 0.21% | 113 |
|
|
2020
Q1 | – | Sell |
-1,813
| Closed | -$263K | – | 212 |
|
|
2019
Q4 | $263K | Hold |
1,813
| – | – | 0.03% | 207 |
|
|
2019
Q3 | $242K | Sell |
1,813
-123
| -6% | -$15.9K | 0.03% | 181 |
|
|
2019
Q2 | $221K | Hold |
1,936
| – | – | 0.03% | 180 |
|
|
2019
Q1 | $240K | Buy |
+1,936
| New | +$220K | 0.03% | 180 |
|
|
2018
Q4 | – | Sell |
-1,957
| Closed | -$250K | – | 198 |
|
|
2018
Q3 | $250K | Sell |
1,957
-278
| -12% | -$33.1K | 0.03% | 186 |
|
|
2018
Q2 | $242K | Sell |
2,235
-520
| -19% | -$56.6K | 0.03% | 188 |
|
|
2018
Q1 | $292K | Sell |
2,755
-227
| -8% | -$26.4K | 0.03% | 182 |
|
|
2017
Q4 | $349K | Sell |
2,982
-283
| -9% | -$32K | 0.04% | 160 |
|
|
2017
Q3 | $371K | Sell |
3,265
-7,408
| -69% | -$855K | 0.05% | 170 |
|
|
2017
Q2 | $1.33M | Sell |
10,673
-40,708
| -79% | -$4.83M | 0.18% | 102 |
|
|
2017
Q1 | $6.09M | Sell |
51,381
-441
| -0.9% | -$50K | 0.83% | 37 |
|
|
2016
Q4 | $5.19M | Buy |
51,822
+10,630
| +26% | +$1.14M | 0.76% | 48 |
|
|
2016
Q3 | $5.2M | Sell |
41,192
-33
| -0.1% | -$4.08K | 0.28% | 107 |
|
|
2016
Q2 | $4.82M | Sell |
41,225
-6,524
| -14% | -$738K | 0.28% | 118 |
|
|
2016
Q1 | $4.94M | Sell |
47,749
-587
| -1% | -$56.8K | 0.28% | 113 |
|
|
2015
Q4 | $4.81M | Sell |
48,336
-2,336
| -5% | -$229K | 0.27% | 110 |
|
|
2015
Q3 | $4.62M | Buy |
50,672
+762
| +2% | +$76.4K | 0.28% | 112 |
|
|
2015
Q2 | $5.29M | Sell |
49,910
-1,359
| -3% | -$150K | 0.28% | 110 |
|
|
2015
Q1 | $5.85M | Buy |
51,269
+36
| +0.1% | +$4.11K | 0.31% | 109 |
|
|
2014
Q4 | $5.64M | Sell |
51,233
-646
| -1% | -$68.1K | 0.32% | 110 |
|
|
2014
Q3 | $5.07M | Sell |
51,879
-13,848
| -21% | -$1.36M | 0.28% | 122 |
|
|
2014
Q2 | $6.63M | Sell |
65,727
-480
| -0.7% | -$46.8K | 0.36% | 99 |
|
|
2014
Q1 | $6.08M | Buy |
66,207
+87
| +0.1% | +$8.02K | 0.34% | 107 |
|
|
2013
Q4 | $5.98M | Sell |
66,120
-11,649
| -15% | -$1.01M | 0.33% | 106 |
|
|
2013
Q3 | $6.2M | Sell |
77,769
-2,882
| -4% | -$227K | 0.36% | 108 |
|
|
2013
Q2 | $5.87M | Buy |
+80,651
| New | +$6.03M | 0.37% | 113 |
|
Other funds holding ZBH
Boston Common Asset Management's ZBH Position: Q2 2025 in Review
Boston Common Asset Management sold out of Zimmer Biomet (ZBH) in Q2 2025, closing a stake of 60,353 shares — an estimated $6.83M sold.
Boston Common Asset Management first reported a position in ZBH in Q2 2013 and held it in 41 quarters. The position peaked at $17.2M in Q4 2022. 934 funds tracked by Wall St. Rank hold ZBH as of Q2 2025.
- Boston Common Asset Management reported no remaining Zimmer Biomet position as of Q2 2025 after selling out during the quarter.
- Boston Common Asset Management sold 60,353 Zimmer Biomet shares in Q2 2025, an estimated $6.83M.
- Boston Common Asset Management first reported a position in Zimmer Biomet in Q2 2013 and held it in 41 quarters.
- Boston Common Asset Management's Zimmer Biomet position peaked at $17.2M in Q4 2022.
- 934 funds tracked by Wall St. Rank held Zimmer Biomet as of Q2 2025.
Based on Boston Common Asset Management's 13F filing for Q2 2025, filed 22 Jul 2025.